Cryosite Limited reported an 18% rise in FY2026 revenue to $16.7 million, with EBITDA growing 27% amid completed and ongoing facility expansions. The company aims to convert new capacity into client growth in FY2027.
- Revenue up 18% to $16.7 million
- EBITDA increases 27% to $4.3 million
- Ferndell Street cool room expansion completed
- Adderley Street facility build out progressing
- Focus on converting capacity into client activity
Stronger Earnings Outpace Revenue Growth
Cryosite Limited (ASX:CTE) closed FY2026 with a notable 18% increase in revenue to $16.7 million, while EBITDA surged 27% to $4.3 million. This divergence signals improved operational efficiency, driven by higher capacity utilisation at its Ferndell Street headquarters and expanding margins. The company’s EBITDA margin rose nearly two percentage points to 25.7%, reflecting better cost control or pricing power.
June wrapped the year with $1.5 million in revenue and $0.4 million EBITDA, maintaining momentum through the final quarter. Net profit after tax grew 20% to $2.3 million, with a modest lift in NPAT margin to 13.5%.
Facility Expansion Underpins Growth Strategy
The Ferndell Street site, Cryosite’s core facility in South Granville, NSW, completed its cool room expansion capable of maintaining temperatures between 2°C and 8°C. This upgrade enhances capacity for clinical trial and biological storage, a crucial service in the temperature-controlled logistics sector.
Meanwhile, build out of the larger Adderley Street facility in nearby Auburn is progressing well. Spanning approximately 2,100 square metres with a 9.1-metre clearance, this site is designed to support expanded clinical trial services, medical device logistics, and pallet storage. Cryosite’s management emphasises converting this additional space into client contracts as the primary focus for FY2027.
Strong Client Pipeline and Operational Readiness
With the expanded Ferndell Street cool room now operational and Adderley Street nearing readiness, Cryosite is positioning itself to capitalise on a robust client pipeline. The company’s specialised services include importation, storage, labelling, distribution, and reverse logistics for ambient to ultra-frozen clinical trial materials, reflecting a niche expertise in a growing healthcare logistics market.
These results remain unaudited and subject to the final FY2026 audit process. However, the company’s trajectory aligns with its prior announcements of capacity doubling and infrastructure investment, underscoring a deliberate strategy to scale in response to rising demand for outsourced clinical trial logistics.
Bottom Line?
Cryosite’s ability to convert new facility capacity into client contracts will be a key determinant of whether the current momentum translates into sustained growth in FY2027.
Questions in the middle?
- How quickly will Cryosite convert Adderley Street capacity into revenue-generating contracts?
- What impact will the completed cool room expansion have on client retention and pricing?
- Will the final audited results confirm the unaudited earnings growth and margin expansion?